�ٺ���Ƶ

In a related story, researchers from �ٺ���Ƶ and elsewhere report the development of two genetically engineered vaccines to combat the mosquito-borne Rift Valley fever, devastating to livestock and so far confined to Africa and the Middle East. The virus can sicken people, too, who can be infected by mosquitoes or by direct contact with infected animals or their meat. Read more about the .

The spread of dengue fever in northern Australia may be controlled by a bacterium that infects mosquitoes that harbor the virus, Australian and U.S. researchers report Aug. 25 in two papers published in the journal Nature.

The result grew out of work more than 20 years ago by population biologist Michael Turelli, professor of evolution and ecology at �ٺ���Ƶ, and Ary Hoffmann, now at the University of Melbourne, Australia, who are among the coauthors of one of the new Nature papers.

Turelli and Nick Barton of the Institute of Science and Technology, Austria, also describe the mathematical basis of the dengue elimination project in a paper to be published in the journal American Naturalist in September.

Dengue fever is caused by four virus strains spread by the mosquito Aedes aegypti. The disease causes high fever and has been called “breakbone fever” because of the joint aches and muscle pains it causes. Dengue viruses can also cause a potentially fatal disease, dengue hemorrhagic fever, in people who have previously been infected with a different strain of the virus.

Dengue viruses are found throughout the tropics and subtropics and appear annually in northern Australia. The researchers released mosquitoes infected with the bacterial parasite Wolbachia, which suppresses the virus, and now report that the Wolbachia parasite spreads rapidly through the wild mosquito population.

“The results show we can completely transform local populations in a few months,” Turelli said.

Wolbachia is transmitted by female mosquitoes to their offspring. A pair of infected mosquitoes produce slightly fewer eggs than an uninfected couple, but when an infected male mosquito mates with an uninfected female, she produces no eggs at all. That provides a big reproductive advantage to the spread of Wolbachia-infected mosquitoes, generation by generation.

“It’s natural selection on steroids,” Turelli said.

It turns out that Wolbachia also suppresses various other microbes living in the same mosquito – including the dengue virus. As these virus-resistant mosquitoes spread through the wild population, dengue transmission should dry up.

Turelli and Hoffmann first described what turned out to be Wolbachia spreading among Drosophila flies in California’s Central Valley in 1991, and Barton developed much of the relevant mathematics in the late 1970s while trying to understand the genetics of grasshoppers in the French Alps. That basic research by Turelli, Hoffman and Barton provides the biological and mathematical basis for the dengue control strategy.

“At the time, none of us expected that this original research might contribute to human health. This is very exciting, once-in-a-lifetime opportunity,” Turelli said. “We never thought this would turn into an eradication project.”

The mathematics is complicated because when Wolbachia is rare, its spread through an insect population is disadvantaged because infected couples lay fewer eggs than uninfected. However, once the frequency of the infection crosses a certain threshold, there is a strong advantage to its spread.

Originally, Turelli and other researchers lead by Scott O’Neill at the University of Queensland, funded by the Bill & Melinda Gates Foundation, tried to use Wolbachia to shorten the lifespan of Aedes so that the virus would not have the 12 days necessary to develop. However, that approach seems unlikely to work, based on the mathematics of the spread of that type of Wolbachia.

Instead, the team found that Wolbachia itself suppresses certain viruses. The Gates Foundation is providing further funding to support release of infected mosquitoes in Australia, Vietnam and Thailand.

Hoffmann is first author of the Nature paper on which Turelli is a coauthor, and O’Neill is the last (senior) author. Other authors are affiliated with the University of Queensland, Brisbane; Monash University, Melbourne; University of Melbourne; James Cook University, Cairns; and the Queensland Institute of Medical Research, Brisbane, Australia.

The research was supported grants from the Grand Challenges in Global Health Initiative of the Bill and Melinda Gates Foundation; The National Health and Medical Research Council, Australia; the Queensland Government; the U.S. National Institutes of Health; the Commonwealth Scientific and Industrial Research Organization (CSIRO), Australia; the U.S. National Science Foundation and fellowships from the Australian Research Council.